Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Clemmons

Showing results (31-40 of 113) with videos related to

Pageof 12
Sort By:
Endocrinology|June 16, 2011
Suppression of AMPK activation via S485 phosphorylation by IGF-I during hyperglycemia is mediated by AKT activation in vascular smooth muscle cellsJunyu Ning, Gang Xi, David R Clemmons
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|October 13, 2009
The current status of IGF-I assays--a 2009 updateJan Frystyk, Pamela Freda, David R Clemmons
The Journal of Biological Chemistry|January 6, 2010
p66shc inhibits insulin-like growth factor-I signaling via direct binding to Src through its polyproline and Src homology 2 domains, resulting in impairment of Src kinase activationGang Xi, Xinchun Shen, David R Clemmons
Plos One|June 16, 2017
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trialDavid R Clemmons, Sam Miller, Jean-Claude Mamputu
Molecular Endocrinology (Baltimore, Md.)|June 7, 2003
Tyrosine phosphorylation of the beta3-subunit of the alphaVbeta3 integrin is required for embrane association of the tyrosine phosphatase SHP-2 and its further recruitment to the insulin-like growth factor I receptorYan Ling, Laura A Maile, David R Clemmons
The Journal of Biological Chemistry|February 9, 2002
Increases in free, unbound insulin-like growth factor I enhance insulin responsiveness in human hepatoma G2 cells in cultureKeiji Sakai, Henry B Lowman, David R Clemmons
Endocrinology|November 12, 2015
IGF-I and IGFBP-2 Stimulate AMPK Activation and Autophagy, Which Are Required for Osteoblast DifferentiationGang Xi, Clifford J Rosen, David R Clemmons
Cellular and Molecular Life Sciences : CMLS|June 4, 2010
Recruitment of Pyk2 to SHPS-1 signaling complex is required for IGF-I-dependent mitogenic signaling in vascular smooth muscle cellsXinchun Shen, Gang Xi, Yashwanth Radhakrishnan, et al.
The Journal of Biological Chemistry|March 20, 2015
The coordinate cellular response to insulin-like growth factor-I (IGF-I) and insulin-like growth factor-binding protein-2 (IGFBP-2) is regulated through vimentin binding to receptor tyrosine phosphatase β (RPTPβ)Xinchun Shen, Gang Xi, Christine Wai, et al.
Molecular Biology of the Cell|September 16, 2003
The association between integrin-associated protein and SHPS-1 regulates insulin-like growth factor-I receptor signaling in vascular smooth muscle cellsLaura A Maile, Jane Badley-Clarke, David R Clemmons
Pageof 12

Showing results (31-40 of 113) with videos related to

Sort By:
Pageof 12
Endocrinology|June 16, 2011
Suppression of AMPK activation via S485 phosphorylation by IGF-I during hyperglycemia is mediated by AKT activation in vascular smooth muscle cellsJunyu Ning, Gang Xi, David R Clemmons
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|October 13, 2009
The current status of IGF-I assays--a 2009 updateJan Frystyk, Pamela Freda, David R Clemmons
The Journal of Biological Chemistry|January 6, 2010
p66shc inhibits insulin-like growth factor-I signaling via direct binding to Src through its polyproline and Src homology 2 domains, resulting in impairment of Src kinase activationGang Xi, Xinchun Shen, David R Clemmons
Plos One|June 16, 2017
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trialDavid R Clemmons, Sam Miller, Jean-Claude Mamputu
Molecular Endocrinology (Baltimore, Md.)|June 7, 2003
Tyrosine phosphorylation of the beta3-subunit of the alphaVbeta3 integrin is required for embrane association of the tyrosine phosphatase SHP-2 and its further recruitment to the insulin-like growth factor I receptorYan Ling, Laura A Maile, David R Clemmons
The Journal of Biological Chemistry|February 9, 2002
Increases in free, unbound insulin-like growth factor I enhance insulin responsiveness in human hepatoma G2 cells in cultureKeiji Sakai, Henry B Lowman, David R Clemmons
Endocrinology|November 12, 2015
IGF-I and IGFBP-2 Stimulate AMPK Activation and Autophagy, Which Are Required for Osteoblast DifferentiationGang Xi, Clifford J Rosen, David R Clemmons
Cellular and Molecular Life Sciences : CMLS|June 4, 2010
Recruitment of Pyk2 to SHPS-1 signaling complex is required for IGF-I-dependent mitogenic signaling in vascular smooth muscle cellsXinchun Shen, Gang Xi, Yashwanth Radhakrishnan, et al.
The Journal of Biological Chemistry|March 20, 2015
The coordinate cellular response to insulin-like growth factor-I (IGF-I) and insulin-like growth factor-binding protein-2 (IGFBP-2) is regulated through vimentin binding to receptor tyrosine phosphatase β (RPTPβ)Xinchun Shen, Gang Xi, Christine Wai, et al.
Molecular Biology of the Cell|September 16, 2003
The association between integrin-associated protein and SHPS-1 regulates insulin-like growth factor-I receptor signaling in vascular smooth muscle cellsLaura A Maile, Jane Badley-Clarke, David R Clemmons
Pageof 12